Characterization of Soluble Immune Checkpoint Protein PD-1, PD-L1 and PD-L2 Levels in Different Types of Lymphoid Malignancies

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.

Cancer cells can avoid and suppress immune responses through activation of inhibitory immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4. Blocking the activities of these proteins with monoclonal antibodies, and thus restoring T cell function, has delivered breakthrough therapies against cancer. In this review, we describe the latest work on structural characterization of the checkpoin...

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies

The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immu...

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients

downregulation of immunosuppressive molecules, pd-1 and pd-l1 but not pd-l2, in the patients with multiple sclerosis

programmed cell death-1 (pd-1) and its ligands, pd-l1 and pd-l2, have been regarded as important immune system regulatory molecules. the aberrant expression of the molecules has been related to several autoimmune disorders. this study is aimed to assess the mrna expression level of pd-1, pd-l1, and pd-l2 molecules in the peripheral blood mononuclear mells (pbmcs) from multiple sclerosis (ms) pa...

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far. Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes. The two optimized small-molecule inhib...